MicroRNA expression profiling identifies miR-31-5p/3p as
associated with time to progression in wild-type RAS metastatic
colorectal cancer treated with cetuximab

J 2015

MicroRNA expression profiling identifies miR-31-5p/3p as associated with time to progression in wild-type RAS metastatic colorectal cancer treated with cetuximab

MLČOCHOVÁ, Jitka; Petra VYCHYTILOVÁ; Manuela FERRACIN; Barbara ZAGATTI; Lenka RADOVÁ et. al.

Základní údaje

Originální název

MicroRNA expression profiling identifies miR-31-5p/3p as associated with time to progression in wild-type RAS metastatic colorectal cancer treated with cetuximab

Autoři

Vydání

Oncotarget, Albany, Impact Journals, 2015, 1949-2553

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 5.008

Kód RIV

RIV/00216224:14740/15:00084339

Organizační jednotka

Středoevropský technologický institut

DOI

https://doi.org/10.18632/oncotarget.5735

UT WoS

000366114000021

EID Scopus

2-s2.0-84948783085

Klíčová slova česky

mikroRNA; kolorektální karcinom; cetuximab; miR-31; progrese

Klíčová slova anglicky

microRNA; colorectal cancer; cetuximab; miR-31; progression

Štítky

EL OK, podil, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 3. 5. 2016 17:05, Olga Křížová

Anotace

V originále

The aim of our study was to investigate whether microRNAs (miRNAs) could serve as predictive biomarkers to anti-EGFR therapy (cetuximab, panitumumab) in patients with RAS wild-type (wt-RAS) metastatic colorectal cancer (mCRC). Historical cohort of 93 patiens with mCRC (2006–2009) was included and further divided into exploratory and validation cohorts. MiRNAs expression profiling was performed on the exploratory cohort of 41 wt-KRAS mCRC patients treated with cetuximab to identify miRNAs associated with time to progression (TTP). The validation was performed on two independent cohorts: 28 patients of wt-RAS mCRC treated with cetuximab and 24 patients of wt-RAS mCRC treated with panitumumab. We identified 9 miRNAs with significantly different expression between responders and non-responders to cetuximab therapy (P < 0.01). These 9 miRNAs were further evaluated in two independent cohorts of patients and miR-31-3p (P < 0.001) and miR-31-5p (P < 0.001) were sucessfully confirmed as strongly associated with TTP in wt-RAS mCRC patients treated with cetuximab but not panitumumab. When evaluated on the complete cohort of cetuximab patients (N = 69), miR-31-3p (HR, 5.10; 95% CI, 2.52–10.32; P < 0.001) and miR-31-5p (HR, 4.80; 95% CI, 2.50–9.24; P < 0.001) were correlated with TTP on the comparable level of significance. There was no difference in miR-31-5p/3p expression levels in RAS mutated and wild-type tumor samples. MiR-31-5p/3p are promising predictive biomarkers of cetuximab response in wt-RAS mCRC patients.

Návaznosti

ED1.1.00/02.0068, projekt VaV

Název: CEITEC - central european institute of technology

Přiložené soubory

ZVV_2015_205_1314693_MicroRNA_expression_01.pdf

Požádat o autorskou verzi souboru

Citovat

MLČOCHOVÁ, Jitka; Petra VYCHYTILOVÁ; Manuela FERRACIN; Barbara ZAGATTI; Lenka RADOVÁ; Marek SVOBODA; Radim NĚMEČEK; Stanislav JOHN; Igor KISS; Rostislav VYZULA; Massimo NEGRINI a Ondřej SLABÝ. MicroRNA expression profiling identifies miR-31-5p/3p as associated with time to progression in wild-type RAS metastatic colorectal cancer treated with cetuximab. Oncotarget. Albany: Impact Journals, 2015, roč. 6, č. 36, s. 38695-38704. ISSN 1949-2553. Dostupné z: https://doi.org/10.18632/oncotarget.5735.

@article{1314693,
   author = {Mlčochová, Jitka and Vychytilová, Petra and Ferracin, Manuela and Zagatti, Barbara and Radová, Lenka and Svoboda, Marek and Němeček, Radim and John, Stanislav and Kiss, Igor and Vyzula, Rostislav and Negrini, Massimo and Slabý, Ondřej},
   article_location = {Albany},
   article_number = {36},
   doi = {https://doi.org/10.18632/oncotarget.5735},
   keywords = {microRNA; colorectal cancer; cetuximab; miR-31; progression},
   language = {eng},
   issn = {1949-2553},
   journal = {Oncotarget},
   title = {MicroRNA expression profiling identifies miR-31-5p/3p as associated with time to progression in wild-type RAS metastatic colorectal cancer treated with cetuximab},
   url = {http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path[]=5735&pubmed-linkout=1},
   volume = {6},
   year = {2015}
}

TY  - JOUR
ID  - 1314693
AU  - Mlčochová, Jitka - Vychytilová, Petra - Ferracin, Manuela - Zagatti, Barbara - Radová, Lenka - Svoboda, Marek - Němeček, Radim - John, Stanislav - Kiss, Igor - Vyzula, Rostislav - Negrini, Massimo - Slabý, Ondřej
PY  - 2015
TI  - MicroRNA expression profiling identifies miR-31-5p/3p as associated with time to progression in wild-type RAS metastatic colorectal cancer treated with cetuximab
JF  - Oncotarget
VL  - 6
IS  - 36
SP  - 38695-38704
EP  - 38695-38704
PB  - Impact Journals
SN  - 19492553
KW  - microRNA
KW  - colorectal cancer
KW  - cetuximab
KW  - miR-31
KW  - progression
UR  - http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path[]=5735&pubmed-linkout=1
L2  - http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path[]=5735&pubmed-linkout=1
N2  - The aim of our study was to investigate whether microRNAs (miRNAs) could serve as predictive biomarkers to anti-EGFR therapy (cetuximab, panitumumab) in patients with RAS wild-type (wt-RAS) metastatic colorectal cancer (mCRC). Historical cohort of 93 patiens with mCRC (2006–2009) was included and further divided into exploratory and validation cohorts. MiRNAs expression profiling was performed on the exploratory cohort of 41 wt-KRAS mCRC patients treated with cetuximab to identify miRNAs associated with time to progression (TTP). The validation was performed on two independent cohorts: 28 patients of wt-RAS mCRC treated with cetuximab and 24 patients of wt-RAS mCRC treated with panitumumab. We identified 9 miRNAs with significantly different expression between responders and non-responders to cetuximab therapy (P < 0.01). These 9 miRNAs were further evaluated in two independent cohorts of patients and miR-31-3p (P < 0.001) and miR-31-5p (P < 0.001) were sucessfully confirmed as strongly associated with TTP in wt-RAS mCRC patients treated with cetuximab but not panitumumab. When evaluated on the complete cohort of cetuximab patients (N = 69), miR-31-3p (HR, 5.10; 95% CI, 2.52–10.32; P < 0.001) and miR-31-5p (HR, 4.80; 95% CI, 2.50–9.24; P < 0.001) were correlated with TTP on the comparable level of significance. There was no difference in miR-31-5p/3p expression levels in RAS mutated and wild-type tumor samples. MiR-31-5p/3p are promising predictive biomarkers of cetuximab response in wt-RAS mCRC patients.
ER  -

MLČOCHOVÁ, Jitka; Petra VYCHYTILOVÁ; Manuela FERRACIN; Barbara ZAGATTI; Lenka RADOVÁ; Marek SVOBODA; Radim NĚMEČEK; Stanislav JOHN; Igor KISS; Rostislav VYZULA; Massimo NEGRINI a Ondřej SLABÝ. MicroRNA expression profiling identifies miR-31-5p/3p as associated with time to progression in wild-type RAS metastatic colorectal cancer treated with cetuximab. \textit{Oncotarget}. Albany: Impact Journals, 2015, roč.~6, č.~36, s.~38695-38704. ISSN~1949-2553. Dostupné z: https://doi.org/10.18632/oncotarget.5735.

Přehled o publikaci